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Abstract
The present report constitutes an attempt to improve and
modify the existing clinical evaluation method for new anti-
microbial agents to treat respiratory infections. One year
ago, a general guideline on the clinical evaluation of antimi-
crobial agents to treat respiratory infections was drafted in
Japanese, leaving scope for critical discussion, and this has
been translated into English, as there were no major
changes. In this report, respiratory infections have been
discussed under the headings “acute respiratory tract infec-
tion” and pneumonia and acute exacerbation of chronic
pulmonary diseases. Standardized criteria were set for the
assessment of severity of infection and effectiveness of the
antimicrobial agent in question. Severity was evaluated on
the basis of a combined assessment of the severity of infec-
tion and severity of the clinical condition of the patients.
Clinical effectiveness of the antimicrobial agent used was
evaluated on the basis of clinical outcome as well as micro-
biological outcome of the trial. Body temperature, local
pain, cough, change in sputum quality, peripheral white
blood cell count, C-reactive protein level, and chest radio-
graph were used as the parameters for the evaluation. To
maintain the quality of specimens to be examined,
Geckler’s classiﬁcation of specimens was used. This report
was constructed based on the analysis of large amounts of
material collected over the years, incorporating internal and
external factors concerning the present evaluation methods.
The newly suggested standardized criteria for clinical evalu-
ation of the new antimicrobial drugs are expected to be
practiced properly hereupon and subjected to further im-
provement if necessary.
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Introduction
The committee for Clinical Evaluation Methods for New
Antimicrobial Agents was established in 1993 after the 41st
general meeting of the Japan Society of Chemotherapy
(June 1993) was concluded. A special meeting was held,
with the aim being international harmonization between
Japan, the United States, and Europe in the area of clinical
evaluation of antimicrobial agents. The guidelines for USA1
and Europe,2 which were presented at the meeting, showed
95% conformity with each other. Before that, in 1991, the
ﬁrst International Conference on Harmonization (ICH)
was held in Brussels, Belgium. However, Japan had its own
guidelines issued by the Ministry of Health and Welfare,
known as Good Clinical Practice (GCP), and this went into
effect from February 1990.3,4 Against this background at
home and abroad, the Director of the Japan Society of
Chemotherapy, Masatoshi Konno, established the Commit-
tee for Clinical Evaluation Methods for New Antimicrobial
Agents as a special committee of the Society. One of the
reasons for the establishment of this special committee was
that despite the advanced level of technical development in
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producing antimicrobial agents in Japan, the clinical evalu-
ation of these new antimicrobial agents has not necessarily
been accepted by the rest of the world. So, it was high time
for Japan to establish its own clinical evaluation methods
for antimicrobial agents which incorporated the viewpoints
on international harmonization. The Committee for Clini-
cal Evaluation Methods for New Antimicrobial Agents
consisted of three separate committees: Committee for the
Respiratory System, Committee for the Urinary System,
and Committee for Preventing Postoperative Infections.
An international meeting was held in 1995 during the 43rd
General Meeting of the Japanese Society of Chemotherapy,
with the aim being international harmonization of the cli-
nical evaluation of antimicrobial therapy. Mr. S. Ragnar
Norrby of Sweden, representing the Committee for Euro-
pean Guidelines, Mr. Murray M. Lumpkin of the Food
and Drug Administration (FDA), United States, and Mr.
William R. Darrow of the Schering Plough Research Insti-
tute, United States, were guest speakers.5–7 On behalf of
Japan, the three Subcommittee Chairmen of the Committee
for Clinical Evaluation Methods for New Antimicrobial
Agents announced the committee reports at that meet-
ing.8–10 The authors of this report belong to the Committee
for the Respiratory System.8
The Committee for the Respiratory system, guided by
the principles of international harmonization, had orga-
nized regular meetings and drafted the general guidelines
for the clinical evaluation of antimicrobial agents in the
light of those issued by the FDA in the USA and the Infec-
tious Diseases Society of America (IDSA).11 The next step
was to investigate various viewpoints in order to establish
the guidelines for Clinical Evaluation Methods for New
Antimicrobial Agents to Treat Respiratory Infections. In
this report, we have attempted to describe and discuss all
the relevant details of the methods that should be adapted
for the clinical evaluation of antimicrobial agents used to
treat respiratory infections.
Clinical evaluation methods in brief
Basic concepts and range of indications
The Clinical Evaluation Methods for New Antimicrobial
Agents to Treat Respiratory Infection was outlined on the
basis of need for international harmonization and also in
conformity with the Japanese good clinical practice (GCP)
standards.12–14
The guidelines of the IDSA involved bacterial infections
of the ﬁve respiratory organs, which are, precisely, strepto-
coccal pharyngitis and tonsillitis, otitis media, paranasal
sinusitis, bronchitis, and pneumonia.1 However, in Japan,
otitis media and paranasal sinusitis are commonly dealt with
in the ﬁeld of ear, nose, and throat (ENT) rather than being
considered as respiratory disease.12,13 Taking this into con-
sideration, respiratory infections were classiﬁed into three
groups: (1) Acute upper respiratory tract infections, in-
cluding acute tonsillitis, acute pharyngitis, acute bronchi-
tis, peritonsillar abscess, and retropharyngeal abscess; (2)
pneumonia; and (3) acute exacerbation of chronic pulmo-
nary diseases. This classiﬁcation is appropriate for the clini-
cal evaluation of antimicrobial agents, particularly during
phase II and III trials and it can also be applied for phase
IV trials.
In infections other than those mentioned above, in par-
ticular, suppurative pulmonary disease, such as lung abscess
and empyema, trials should be undertaken after the respec-
tive standards are established.
Inclusion and exclusion criteria
The criteria for selecting patients for clinical trials were set
with the objective of having better evaluation of the effects
of the trial drug. In this regard, the severity of the patient’s
clinical condition and the severity of the infection itself
were considered carefully. Each particular disease entity
has an individual pattern and, likewise, they have different
standards for selection.
In some patients with acute upper respiratory tract infec-
tion there are some underlying diseases which could impair
the clinical effects of the trial drug. Thus, the standard was
made for this group only on the basis of severity of the
infection itself, without considering the underlying disease,
if any.
So far as other groups, e.g., pneumonia and acute exacer-
bation of chronic pulmonary diseases, are concerned, the
severity of the clinical condition was determined by combin-
ing the severity of the infection itself and that of any under-
lying diseases or complications. In general, the severity of
the patient’s clinical condition is largely inﬂuenced by the
underlying disease severity, which makes it difﬁcult to prop-
erly evaluate the antimicrobial drug under trial. Therefore,
it has been suggested to exclude any patient considered as
“severe” from the clinical evaluation.
Effectiveness of antimicrobial agent
The effectiveness of an antimicrobial agent under trial is
evaluated on the basis of its microbiological effects and
clinical effects. The parameters used are the course of the
etiologic agent and the speed of improvement in signs and
symptoms. The evaluation should be done at two time
points, after 3 and 7 days of treatment. Conventionally, a
trial drug used to be administered for 14 days, but it has
been recognized now that any patient requiring 14 days of
treatment is an exception. According to present standard-
ization, drug administration should be discontinued if an
etiologic agent is considered as eradicated by the 3rd day of
treatment on the basis of clinical and microbiological evalu-
ation. But a subsequent follow-up is necessary. The degree
of leeway allowed regarding the test performance should be
predetermined in the protocol.
The evaluation of microbiological effects is conducted as
per the General guidelines on clinical evaluation of antimi-
crobial drugs, 1996.15 The standards should be recorded in
the protocol in advance. The clinical effects are evaluated as
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an objective standard and divided into two categories: “ef-
fective” and “not effective” instead of extremely effective
and slightly effective. In addition, when the clinical effects
cannot be evaluated for some reason, the remark “evalua-
tion not possible” is to be recorded.
Further, a comprehensive evaluation is conducted on
the basis of clinical effects, microbiological effects, and the
safety (objective and subjective adverse effects and any
test abnormalities). The evaluation methods and standards
should be determined for any particular disease and they
must be prerecorded in the protocol. The evaluation of
safety is conducted in accordance with the General guide-
lines on the clinical evaluation of anti-infective drugs, 199615
and the evaluation standards for adverse reactions and clini-
cal test result abnormalities in clinical trial patients treated
with antimicrobial agents.16
In general, evaluation of the effectiveness of an antimi-
crobial agent is done at the end of treatment (EOT), but the
infection may ﬂare up again and may recur after the EOT,
even though the trial drug was thought to be effective ini-
tially.1 For this reason, physical examination and laboratory
tests should be performed at a deﬁned time period after the
EOT for a ﬁnal evaluation which indicates the end of study
(EOS). For respiratory infection, the appropriate time pe-
riod is suggested to be about 1 week.
Clinical evaluation of new antimicrobial agents
in acute respiratory tract infections
Concept of the disease and indications for clinical
evaluation of antimicrobial agents
Acute upper respiratory tract infections cover range of ill-
ness from common cold to acute bronchitis. Acute bronchitis
is an infective inﬂammation of the respiratory tract extend-
ing downwards from the glottis. It is a lower respiratory tract
infection, but also shares some characteristics which should
be included in the pathophysiology of upper respiratory tract
infections. Clinical evaluation of oral antimicrobial agents
was undertaken in patients with acute tonsillitis, acute
pharyngitis, acute laryngopharyngitis, and acute bronchitis.
Peritonsillar abscess (including severe crypttonsillitis and
peritonsillar inﬂammation) and retropharyngeal abscess
were subject to trial with injectible antimicrobial agents.
Infections accompanied by some underlying chronic respira-
tory diseases are classiﬁed separately.
Most upper respiratory tract infections start initially as a
common cold and frequently the infection descends, involv-
ing the lower respiratory tract. The primary etiologic agents
encountered in common cold are often viruses, as some
viral pathogens, such as rhinovirus, coronavirus, inﬂuenza
virus, adenovirus, coxackievirus, and respiratory syncytial
virus, have a particular predilection for the respiratory
tract.17,18 A secondary bacterial infection may result in the
involvement of lower respiratory tract. However, the distri-
bution of the infectious pathogens varies according to the
site of involvement. In acute tonsillitis and peritonsillar
abscess, the pathogens are -hemolytic streptococcus,
Haemophillus inﬂuenzae, Staphylococcus aureus, and Stre-
ptococcus pneumoniae, in order of frequency.19–21 In acute
pharyngitis,22,23 the most commonly encountered bacteria
are S. pneumoniae and H. inﬂuenzae and then -hemolytic
streptococcus and S. aureus. Among the etiologic agents
of acute bronchitis,24 S. pneumoniae and H. inﬂuenzae are
frequently seen, followed by Moraxella (Branhamella).
Other organisms are S. aureus and -hemolytic streptococ-
cus with a lower frequency of occurrence. Mycoplasma
upper respiratory tract infections are common during the
prevalence period.25 In addition, Chlamydia (Chlamydia
psittaci and Chlamydia pneumoniae) is also involved in
acute respiratory tract infection.26
Patients infected by one of the above pathogens, as diag-
nosed by bacteriological examination, or those who are
highly suspected to be infected but still not conﬁrmed are
appropriate subjects to include in a clinical trial of new
antimicrobial agents. Patients with insigniﬁcant microbio-
logical test results, but having signs and symptoms of acute
respiratory tract infection, such as high WBC count or pro-
ductive cough of purulent nature are also suitable for inclu-
sion in the trial.
In Mycoplasma and Chlamydia infections the host re-
sponse, as well as the physical evidence, is mild and, inter-
estingly, recovery is also slow even after treatment with an
antimicrobial agent. In these patients, standards for in-
clusion in and evaluation of the trial should be set out
separately.
Diagnostic standards
Microbiological diagnostic standards
It is very important to determine the etiologic agents in
patients with respiratory infection who are selected as sub-
jects for a trial for clinical evaluation of a new antimicrobial
agent. The most important and commonly used methods for
identifying an infectious pathogen, are microscopic exami-
nation of smears and culture of specimens in appropriate
media. The sample should be collected with a sterile cotton
swab before administration of the antimicrobial agent is
commenced. The swab should be scratched along the poste-
rior pharyngeal wall and uvula, and the surface of the sup-
purating tonsils in patients with pharyngitis and tonsillitis,
respectively, to collect a sample. The sample is then cul-
tured in an appropriate medium, e.g., blood agar medium,
for 16–18h at 37°C. In acute bronchitis, the sample is ob-
tained from the purulent area of the sputum and is cultured
as described above. Samples that may be contaminated
with normal ﬂora in the upper respiratory tract should be
excluded to avoid the probability of error in evaluation. A
specimen with 25 or more leucocytes and 10 or less epithe-
lial cells per visual ﬁeld (100  magniﬁcation) is extremely
likely to be expectorated from a lesion and the probability
of identiﬁcation of the etiologic agent is also extremely high.
If the specimen does not satisfy the above conditions iden-
tiﬁcation of the etiologic pathogen will be less likely. There-
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Acute tonsillitis. Reddening and swelling of tonsils with
pustules on the surface.
Acute pharyngitis. Local pain, reddening and swelling of
the uvula and throat and a purulent exudation. Many pa-
tients do not exhibit these typical features.
Acute bronchitis. Chest pain and cough, often productive
and purulent, are the cardinal features.31
Diagnosis of acute upper respiratory tract infection de-
pends on the isolation of a pathogenic bacteria in a suitable
specimen from a patient having some of the characteristic
features appropriate for the site of involvement. In case of
failure to identify any signiﬁcant bacteria by microbiologi-
cal testing, other clinical and pathological ﬁndings should be
considered collectively for the diagnosis. If the leukocyte
count is 8000/mm3 or higher, CRP is 0.7mg/dl or higher, and
a purulent-productive cough or-exudate is present, then
it is obvious that the pathology is of bacterial and not viral
origin. Sometimes the erythrocyte sedimentation rate
(ESR) is of accessory value, although it is increased in many
other conditions and therefore should be performed with
other diagnostic tests.
Diagnosis of acute respiratory tract infection by Myco-
plasma and Chlamydia is relatively difﬁcult, in contrast to
that of pneumonia, in which a fairly reliable diagnosis can
be made with the help of a chest X-ray. Laboratory tests
reveal a reduced WBC count in many patients, which leads
to confusion with viral infection. As culture methods are
not well practiced, a reliable diagnosis needs the detection
of the antibody titer for a speciﬁc antigen or DNA of the
pathogen in the serum. Precisely, a fourfold or higher in-
crease in Mycoplasma antibody titers is observed between
blood samples taken during the onset of the disease and
during the convalescent period (usually after 2 weeks), or a
rise of 64 times or higher and 320 times or higher in comple-
ment ﬁxation (CF) and indirect hemagglutination (IHA)
antibody titers, respectively, in a single sample is diagnostic
of Mycoplasma infection. Similarly, in Chlamydia infection,
a fourfold or higher rise in the CF antibody in paired serum
samples or a 16-fold or higher increase in a single sample is
diagnostic of Chlamydia infection. Detection of antibodies
or DNA in the serum by ﬂuorescence antibody technique,
enzyme antibody technique, DNA probes, or the poly-
merase chain reaction (PCR) technique can also be used as
alternative diagnostic tests for Mycoplasma and Chlamydia
infection.
Inclusion criteria for the target population
Bacteriological infection
Target subjects for clinical evaluation of antimicrobial
agents should satisfy criterion (1) and at least any two crite-
ria from (2) to (5), as described below.
(1) The suspected etiologic agent is isolated from a suitable
specimen or there is a strong possibility of its presence.
Patients from whom a good sample has been obtained
Table 1. Geckler’s 27 classiﬁcation of specimens for quality control
Group WBC count/ Squamous epithelial
visual ﬁelda cells/visual ﬁelda
1 10 25
2 10–25 25
3 25 25
4 25 10–25
5 25 10
6b 25 25
a Observed at 100  magniﬁcation
b Transtracheal aspiration method used in patients with gran-
ulocytopenia
fore, quality control of the specimen is very important, and
some references such as Geckler et al.27 (Table 1) and
Ogihara’s classiﬁcation28 should be used as guidance. Dem-
onstration of bacteria within phagocytic cells (neutrophils
or macrophages) in a particular specimen is the best evi-
dence to establish diagnosis and such samples should be
stored for future re-evaluation.
Various methods are used for culture tests of sputum,
including the washing culture method and the quantitative
culture method, and a combination of one of these methods
with another procedure yields a higher probability of de-
tecting an etiologic agent. Detection by the quantitative
culture method of a microbial pathogen at 107 CFU/ml or
more in a specimen is indicative of that organism being the
etiologic agent. But an organism present in numbers lower
than 107/ml in a specimen obtained following the standard
procedure with a minimal amount of normal oral ﬂora con-
tamination may also be the etiologic agent. The culture
should be continued for 24h in case of absence of any visible
colony. Some cultures demand special condition; for ex-
ample, carbon dioxide gas culture yields a higher detection
frequency of -hemolytic streptococcus. Even though diag-
nosis by quick diagnostic kit is performed for some patho-
gens, the culture test method is still the most dependable
and must be performed to conﬁrm a diagnosis. Similarly,
in Mycoplasma and Chlamydia infection, diagnosis can be
done by serological tests,29,30 but it is better to conﬁrm the
ﬁndings by culture test during an ongoing trial of antimicro-
bial agents.
Clinical diagnostic standards
The most common signs and symptoms of acute bacterial
upper respiratory tract infection are fever, purulent produc-
tive cough, and pustules or abscess in the upper respiratory
tract. It can be reasonably concluded that a suppurative
inﬂammatory condition is present when the white blood
cell count rises to 8000/mm3 or higher, there is migration
of nuclei to the left, and there is an increase in C-reactive
protein (CRP) to 0.7 mg/dl or higher. It can be discrimi-
nated from a viral condition, in which fever is accompanied
by mucoid exudate and sputum, no or mild increase in CRP,
and leukopenia in many patients. The characteristic fea-
tures of individual diseases may be summarized as listed
below:
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(pustules/ purulent exudate/ purulent sputum) even
though the etiologic agent is not conﬁrmed.
(2) A white blood cell count of  8000/mm3.
(3) Stab leukocytes of  10%.
(4) CRP  0.7mg/dl (or a value which exceeds the maxi-
mum value at the facility).
(5) Body temperature, 37°C.
Mycoplasma and Chlamydia infection
Target subjects for clinical evaluation of antimicrobial
drugs with Mycoplasma and Chlamydia infection should
have the signs and symptoms described in the previous
section for acute bacterial upper respiratory tract infection
and must satisfy criterion (1) and at least three of the re-
maining six criteria as described below:
(1) A fourfold or higher increase in Mycoplasma antibody
titers in paired serum samples, or 64 times or higher
increase in CF antibody titers, or 320 times or higher
increase in HA titers in a single serum sample. Patients
exhibiting a fourfold or higher increase in Chlamydia
antibody titers in paired serum samples, or 16 times or
higher increase in CF antibody titers in a single sample.
Patients tested positive for Mycoplasma or Chlamydia
by antigen or gene detection techniques as described
before.
(2) A white blood cell count of  8000/mm3.
(3) Stab leukocytes of  10%.
(4) CRP of  0.7mg/dl (or a value which exceeds the maxi-
mum value at the facility).
(5) Body temperature of  37°C.
(6) A persistent cough.
(7) Pain at the local site of inﬂammation.
However, in many patients the results related to criterion
(1) are available 1–2 weeks after commencement of treat-
ment, and thus some patients who do not satisfy the stan-
dard criteria are also included in the trial. Such patients
should be excluded immediately and should be treated with
another suitable antimicrobial agent. Furthermore, care
should be taken to avoid misinterpretation of the antibody
titer test due to cross reaction between different genuses
of Chlamydia, with particular attention to C. trachomatis
which frequently complicates urinary tract infections.
Standards for severity evaluation
Acute upper respiratory tract infections are mostly mild or
moderate in severity, although a few may become severe.
To categorize the degree of severity, indicators have been
determined and they are interpreted as shown in Table 2.
The indicators are body temperature, white blood cell
count, and CRP value. Ideally, the indicators should be
assessed on the day of and 1 day prior to commencing the
clinical trial for the antimicrobial agent and the highest
values for the indicators between these 2 days should be
selected.
Table 2. Standardized criteria for evaluation of severity in patients
with acute upper respiratory tract infection
Parameters Severity of disease
Milda Moderateb Severec
Body temperature (°C) 37.5 38.6
Peripheral white blood 10000/mm 15000
cell count (/mm3)
CRP (mg/dl) 4.0 10.0
a Satisﬁes two or more of the deﬁned criteria
b Cases which are neither mild nor severe
c Satisﬁes two or more of the deﬁned criteria
Standards for efﬁcacy evaluation
It is difﬁcult to set standards for evaluation of efﬁcacy.
However, this is done on the basis of clinical and microbio-
logical test ﬁndings. Usually, administration of antimicro-
bial agents for 4–7 days is sufﬁcient for mild and moderate
acute upper respiratory tract infection of bacterial origin.
But in severe infections or in Mycoplasma or Chlamydia
infections the drug may be continued for as long as 14 days.
In general, clinical improvement is observed by subsiding
fever and lowering of white blood cell count and CRP value.
The ESR may also be used as an indicator for evaluating
drug efﬁcacy, although it is affected by conditions other
than infection alone. The speed of recovery should be as-
sessed for the evaluation of drug efﬁcacy. Precisely, a 3-day
and a 7-day evaluation should be conducted. The evaluation
is made on the basis of the clinical and microbiological
assessment. When the microbiological effects are equivocal,
the evaluation is made on the priority basis of clinical as-
sessment. In severe bacterial infections or Mycoplasma or
Chlamydia infections a ﬁnal day evaluation is conducted
after a maximum of 14 days, in addition to the 3-day and 7-
day evaluation.
Standards for evaluation of microbiological outcome
Patients meeting the inclusion criteria and compliant with
the regimen are submitted to 3-day and 7-day evaluation
(on-therapy evaluation) after the regimen has started and
a ﬁnal evaluation after the etiologic agent is determined
and the drug regime is over (end-of-therapy evaluation).
To assess further, a post-therapy evaluation is done at
least 7 days after the completion of the therapy (test-of-cure
evaluation). The following concepts are used for the evalu-
ation:
(a) Presumed eradication. A bacterial outcome should be
extrapolated from a clinical outcome in this condition.
(b) Documented eradication. Absence of the etiologic
agent from the cultured specimen after the regimen.
(c) Persistence. Presence of the etiologic pathogen even
after the complete course of antimicrobial agent therapy.
The MIC of the trial drug as well as that of standard drugs
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should be assessed to determine the resistance of the con-
cerned pathogen.
(d) Recurrence. Isolation of the original pathogens from a
culture after the test-of-cure culture while previous culture
was negative. The originality of the pathogen should be
carefully veriﬁed and if necessary, in-vivo sensitivity should
be assessed to compare the patterns.
(e) Reduction. Quantitative reduction of the original
pathogen as veriﬁed by a quantitative culture technique.
(f) Partial eradication. Disappearance of one or more mi-
crobes after treatment in an infection involving multiple
pathogens. It is very important to conﬁrm the involvement
of multiple pathogens for evaluation.
(g) Superinfection. Isolation of a pathogen other than the
original pathogen from a specimen taken while the patient
is on therapy in a patient who has signs and symptoms of
infection.
(h) Apparent new infection. Isolation of a new pathogen
from a site of infection without clear signs and symptoms
while the original pathogen is eradicated by antimicrobial
treatment.
(i) New infection. Isolation of a new pathogen from a site
with clear signs and symptoms of infection while the origi-
nal pathogen is eradicated by antimicrobial treatment.
(j) Evaluation not possible. When a patient is not in confor-
mity with any of the above conditions for various reasons.
Standards for evaluation of clinical outcome
The patients should be evaluated clinically for the effective-
ness of the trial antimicrobial agent 3 days and 7 days after
initiation of the therapy. The outcome may be categorized
as “effective” or “ineffective” on the basis of the standard-
ized criteria shown in Tables 3 and 4. Acute upper respira-
tory tract infection may be of bacterial or nonbacterial
origin and hence they have been evaluated by different
standards.
(a) Acute bacterial upper respiratory tract infections. A
drug may be evaluated as effective when all or two of three
criteria (Table 3) are satisﬁed and the third one has not
worsened. The drug is usually given for 7 days initially. If
after 3-day and 7-day evaluations at least two of the three
criteria are fulﬁlled, the drug may be continued for another
7 days at maximum. Fulﬁllment of the standards during this
period indicates the effectiveness of treatment. On the con-
trary, failure to achieve the standards at any time point
indicates that the treatment is ineffective. The drug should
be discontinued and another appropriate antimicrobial
drug should be started without delay. Failure to pursue an
evaluation for any reason leads to a conclusion of “evalua-
tion not possible”.
(b) Acute nonbacterial upper respiratory tract infections
(Mycoplasma and Chlamydia). The evaluation of acute
nonbacterial upper respiratory tract infections is done on
the basis of the standardized criteria as shown in Table 4. A
drug may be evaluated as effective when all of the ﬁve, or
three or four of the ﬁve criteria are satisﬁed and the others
are not worsened. Evaluation time and procedure are the
same as those used for acute bacterial upper respiratory
tract infections.
Final evaluation
The clinical evaluation of an antimicrobial agent should be
conducted during and after the completion of therapy, as
described in the section clinical evaluation methods in brief,
subsection, Effectiveness of antimicrobial agent. However,
sometimes a post-therapy evaluation is conducted after a
deﬁned time period depending on the pathology and the
pathogen involved. In some instances of acute bacterial
or Mycoplasma or Chlamydia infections, initial therapy is
proved to be effective but is followed by a recurrence. Thus,
ﬁnal evaluation of an antimicrobial agent is quite difﬁcult
and it is therefore important to continue the follow-up ex-
aminations and laboratory testing for a deﬁned time period.
In acute upper respiratory tract infections, a 7-day post-
therapy follow-up is considered to be appropriate and this
should be described in the protocol in advance.
Clinical evaluation of new antimicrobial agents
in pneumonia
Pneumonia is frequently subjected to clinical evaluation for
new antimicrobial agents. This section deals with determin-
Table 3. Evaluation of effectiveness of new antimicrobial agents in
patients with acute bacterial upper respiratory tract infections
Parameters Criteria of effectiveness
Body temperature Improvement to 37°C
White blood cell Improvement to 8000/mm3 or to the facility’s
count normal range
CRP Improvement to 30% or less of the previous
value
Table 4. Evaluation of effectiveness of new antimicrobial agents in
patients with acute nonbacterial upper respiratory tract infections
Parameter Criteria of effectiveness
Body temperature Improvement to 37°C
White blood cell Improvement to 8000/mm3 or to the facility’s
count normal range
CRP Improvement to 30% or less of the previous
value
Persistent cough Disappeared
Throat pain Relieved
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ing the inclusion criteria to select patients appropriate for
evaluation, to set evaluation standards for severity of the
disease and efﬁcacy of the antimicrobial drug. Moreover,
the parameters used to assess the above determinants are
also set down.
Disease concept and indications for clinical evaluation
of antimicrobial drugs
Pneumonia is deﬁned as an acute infection of the pulmo-
nary parenchyma that is associated with at least some symp-
toms of acute infection and accompanied by the presence
of an acute inﬁltrate on a chest radiograph or auscultatory
ﬁndings consistent with pneumonia (such as altered breath
sounds and/or localized rales). The infectious agents in-
volved cover a wide range from aerobic to anaerobic bacte-
ria, Mycoplasma, Chlamydia, and acid fast bacilli, as well as
viruses and fungi.32–35 The frequency of an etiologic agent
varies on host factors (such as age, underlying disease
prevalence), agent factors (types of species), and environ-
mental factors (whether infection acquired in community or
hospital setting).
The pathogenic microbes discussed under this guidance
include general bacteria (such as S. pneumoniae, S. aureus,
H. inﬂuenzae, K. pneumoniae, P. aeruginosa, and
Moraxella), Legionella, Mycoplasma, and Chlamydia.
Pneumonia which is caused by pathogens such as viruses,
fungus, or acid-fast bacilli needs to be evaluated by com-
pletely different diagnostic standards and the standardized
criteria for evaluation of the effectiveness of new agents
also need to be set down.
It is not easy to identify the etiologic pathogens for pneu-
monia, particularly before commencing an antimicrobial
drug, and previous reports indicate that this identiﬁcation
rate is less than 50%. Therefore it is important that the
concerned drug should cover the probable etiologic pa-
thogens. However, a comparatively reliable prediction is
possible on the basis of careful examination of the afore-
mentioned host, agent, and environmental factors, close
monitoring of the clinical conditions (prevalence, age, puru-
lent sputum) and performing appropriate tests (peripheral
white blood cell count, chest X-ray, and gram staining of
a smear specimen of the purulent sputum). When a drug
under trial (such as a macrolide or a new ﬂuoroquinolone)
reasonably covers the spectrum of pathogens (H. inﬂuenzae
and K. pneumoniae, as well as Mycoplasma and Chlamydia)
which are involved in community-acquired infections, it is
not necessary to identify the etiologic pathogen at the be-
ginning of treatment. This identiﬁcation is important with
drugs such as -lactams which target only bacterial infec-
tions. Of course, the importance of various culture tests
and serodiagnosis can not be surpassed. In some cases a
quick diagnosis is now also possible by employing molecular
biology techniques such as the PCR method. Above
all, collecting an appropriate specimen, selection of its cul-
ture methods, and, ﬁnally, proper evaluation is of utmost
importance.36–38
Inclusion criteria for patients
The diagnosis of pneumonia should be based on standard-
ized clinical, radiographic and microbiologic criteria.39
Patients should satisfy at least the following criteria to be
included in an evaluation trial for the clinical effectiveness
of a new antimicrobial agent.
(1) Conﬁrmation of the presence of a new inﬁltrate(s)
on a chest X-ray or computed tomography (CT)
scan.
(2) Conﬁrmation of an existing inﬂammatory condition,
as evidenced by an increased white blood cell
count (WBC  10000/mm3), migration of the nu-
cleus to the left in 10% or more of stab leukocytes,
a raised CRP (1.0mg/dl or more), and an increased
ESR.
Once the above two criteria are satisﬁed, then two of the
four following conditions should be met.
(1) Fever.
(2) Cough, sputum (purulent in nature), chest pain, and
dyspnea.
(3) Auscultatory ﬁndings on pulmonary examination of
rales and/or evidence of pulmonary consolidation
(dullness on percussion, bronchial breath sounds,
or egophony).
(4) A microorganism should be isolated from a specimen of
respiratory secretion after Gram staining and
semiquantitative culture. Supply of a quality specimen
raises the possibility of correctly determining the etio-
logic agent. Specimens of respiratory secretion may be
obtained by any of the following means:
• Deep expectoration
• Nasotracheal aspiration
• Bronchoscopy with bronchoalveolar lavage or protected
brush sampling
• Transtracheal aspiration.
Exclusion criteria
In addition to complying with the general exclusion cri-
teria applicable to other trials, patients enrolled in pneu-
monia trials should be excluded for the following
reasons:
(1) Patients with known bronchial obstruction or a history
of postobstructive pneumonia. (This does not exclude
patients who have chronic obstructive pulmonary
disease.)
(2) Patients with primary lung cancer or another malig-
nancy metastatic to the lungs.
(3) Unless the study is speciﬁcally designed for such a
patient population, patients with cystic ﬁbrosis, AIDS,
known or suspected Pneumocystis carinii pneumonia,
or known or suspected active tuberculosis.
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Table 5. Evaluation of severity of infection in pneumonia
Parameters Severity of disease
Milda Moderateb Severec
Body temperature 37.5°C 38.6°C
Number of inﬁltrates 4 6
on chest radiograph
White blood cell 10000/mm3 15000/mm3
count
CRP 4.0 mg/dl 10.0 mg/dl
a Satisﬁes three or more of the deﬁned criteria
b Cases which are neither mild nor severe
c Satisﬁes three or more of the deﬁned criteria
Severity evaluation standards
The clinical effect of the trial drug is largely inﬂuenced by
the severity of the pneumonia, and the patient’s condition is
evaluated on the basis of the severity of the infection itself
and the severity of underlying diseases and/or complications.
Severity of infection
The severity of pneumonia may be evaluated on the basis of
the standardized criteria such as body temperature, chest X-
ray ﬁndings, peripheral white blood cell count, and CRP, as
shown in Table 5. The criteria for evaluating the severity of
infection are assessed on the day of and the day before
commencing therapy and the higher values of the two are
selected.
It is difﬁcult to rigidly restrict the criteria for mild, mod-
erate, or severe infection. Even when the white blood cell
count is less than 10000/ml3, but the nucleus in 80% or more
of neutrophils and in 20% or more of stab leukocytes has
migrated to the left, the case is evaluated as exceeding the
mild standards. In addition to this, underlying disease fac-
tors such as hematological disorders or liver diseases also
affect the white blood cell count and these should also be
taken into consideration.
To evaluate the severity of pneumonia, chest X-ray is the
most important tool and therefore a precise interpretation
of the ﬁnding is also necessary. A scoring system has been
developed on the basis of the number of inﬁltrating shad-
ows on the chest X-ray, as shown in Table 6 and Fig. 1. Any
pre-existing stromal dysfunction will affect the score and it
is not included in the evaluation.
Severity of underlying diseases and complications
The onset and course of pneumonia is greatly inﬂuenced
by the presence of any underlying disease and its extent.
Therefore, to conduct a proper evaluation of the clinical
effect of a new antimicrobial agent, these factors should be
critically monitored on the basis of some standardized crite-
ria, as listed below:
Mild. No effect on the onset of pneumonia and its course
(such as high blood pressure, hyperlipidemia, or mild liver
dysfunction).
Table 6. Scoring criteria for pneumonia on the basis of chest radio-
graph ﬁndings of area of involvement
Pneumonia Area of involvement
score
0 No abnormal inﬁltrate
1 Very small inﬁltrate which is limited to one intercostal
site
2 Between 1 and 3
3 Inﬁltrate involving 1/10 of one lung
4 Between 3 and 5
5 Inﬁltrate involving 1/3 of one lung
6 Between 5 and 7
7 Inﬁltrate involving 2/3 of one lung
8 Inﬁltrate involving almost one entire lung
9 Between 8 and 10
10 Inﬁltrate involving almost completely both lungs
Fig. 1. Pneumonia score on the basis of involvement of lung area by
inﬁltrates. The black are as in each lung represent the area of involve-
ment by the inﬁltrates. Numerals below the sketches of the lungs indi-
cate the respective scores. See Table 6 for explanation of the score
Moderate. Possibility of affecting the onset and course of
pneumonia but the magnitude is not expected to be severe
(such as mild chronic obstructive pulmonary diseases, well
controlled diabetes, or chronic nephritis).
Severe. Affecting the onset and course of pneumonia sig-
niﬁcantly, as well as the effects of treatment (such as con-
nective tissue diseases, leukemia, malignant diseases
particularly in advanced stages, congestive heart failure,
and chronic airway diseases with respiratory insufﬁciency).
Severity of patient’s condition
The severity of the pneumonia itself and the severity of
underlying diseases or complications are evaluated in com-
bination to conduct a proper evaluation of the severity
of the patient’s condition. The clinical effect of an
atimicrobial agent may be affected considerably by the se-
verity of the patient’s condition and thus a careful analysis
of this factor is mandatory. Even though the severity of an
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which cannot be detected in general bacterial culture.29–40
These pathogens are encountered quite often in trials
targeting pneumonia. It is therefore important to identify
them using special media and selection media, or by sero-
logical tests. The evaluation criteria for serological tests
should be set down beforehand. So far as Mycoplasma
detection is concerned, antibody titers in a paired test
sample taken at the onset of the disease and during the
convalescence stage should show a fourfold or higher
increase. And when a single sample titer is estimated, CF
antibody titers and HA antibody titers should be 64
times and 320 times higher, respectively. Similarly, a diag-
nosis of Chlamydia pneumonia may be made if the CF
antibody titers show a fourfold or higher increase in a
paired test sample or it is 64 times or higher in a single test
sample.41–43 Cold agglutination titers rise simultaneously but
are of limited value as they are also increased due to other
factors.
Pneumonia patients in whom the etiologic agent has
been isolated and identiﬁed should be examined 3 days and
7 days after the onset and on the day of completion of
treatment (maximum 14 days). The evaluation is conducted
on the basis of the standardized criteria as described in the
section “Clinical evaluation of new antimicrobial agents in
acute respiratory tract infection, subsection Standards for
efﬁcacy evaluation; Standards for evaluation of microbio-
logical outcome.”
Standards for evaluation of clinical outcome
The clinical outcome after treatment with a new antimicro-
bial drug is evaluated on the basis of a comparison of the
patient’s baseline signs and symptoms and other laboratory
parameters with those at a later stage. Results of evaluation
may be expressed as “effective”, “ineffective”, and “evalu-
ation not possible”, as described in Table 8.
The evaluation is undertaken 3 days and 7 days after the
beginning of the antimicrobial drug therapy and usually the
drug is discontinued after 7 days of treatment. However,
the results of the assessment of the standard criteria may
not be available within 7 days, particularly in severe pneu-
monia or pneumonia accompanied by underlying diseases,
or moderate or severe complications. In this situation, the
drug may be continued for as long as 14 days, provided a
trend of improvement is observed, as indicated by an im-
provement in chest X-ray and CRP value. The drug may be
considered as effective if there is resolution of all signs and
Table 8. Evaluation standards for efﬁcacy of antimicrobial agents in pneumonia
Parameters Evaluation
Effectivea Ineffective Evaluation not possible
Body temperature Lowered to 37°C
Chest radiograph score Lowered to 70% or less Does not satisfy the efﬁcacy Not possible to evaluate the efﬁcacy
of the previous value standards for any reason
White blood cell count Reduced to 9000/mm3
CRP CRP
a Satisﬁes three or more of the deﬁned criteria
infection itself is of mild or moderate degree the patient’s
condition may be evaluated as severe, provided a parallel
severe underlying disease conditions or complications exist.
These patients are not included in the usual trials for evalu-
ation of antimicrobial drugs and they should be studied
under special trial settings (bold entries in Table 7).
Efﬁcacy evaluation of a new antimicrobial drug
The efﬁcacy of a new antimicrobial drug is evaluated on the
basis of microbiological and clinical outcome.
Standards for evaluation of microbiological outcome
Determining an etiologic agent in pneumonia patients is
quite difﬁcult, particularly in those patients from whom a
good sample of respiratory secretion is not available. In
many patients, and, in particular, during the early stages of
pneumonia, expectoration of purulent sputum is inefﬁcient
and isolation of an etiologic agent is not possible. But it is
very important to identify and follow the course of the
causative pathogen in order to evaluate the clinical effect
of a new antimicrobial agent. Therefore, efforts should be
made to facilitate expectoration through measures such as
the infusion of physiological saline. In some cases of pneu-
monia, a blood culture is useful to identify the etiologic
agent (such as S. pneumoniae and S. aureus). Another fac-
tor which makes isolation of etiologic agents of pneumonia
difﬁcult during trials is pretreatment with some form of
antimicrobial drug. Therefore, patients who have not re-
ceived any antimicrobial drug since the onset of the disease
should be included in the trial.
Special attention should be given to those speciﬁc pa-
thogens, such as Legionella, Mycoplasma, and Chlamydia,
Table 7. Evaluation of severity of patients with pneumonia
Severity of Severity of infection
underlying diseases
and complications Mild Moderate Severe
None Mild Moderate Severe
Mild Mild Moderate Severe
Moderate Moderate Moderate Severe
Severe Severe Severe Severe
Bold entries indicate patients who should be studied under special trial
settings
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symptoms of pneumonia and improvement or lack of pro-
gression of all abnormalities on chest radiograph.
In patients with accompanying underlying disease or
complications, complete resolution is not achieved, and the
standardized criteria are not satisﬁed (in particular, CRP
value and body temperature) during this 14 days. In such
patients, it is necessary to provide objective proof of im-
provement after treatment to evaluate the drug as “ef-
fective”, such as comparable records prior to onset of
pneumonia and after the treatment. The clinical effect of
the study drug should be evaluated as early as 3 days after
the commencing of treatment, and the speed of clinical
recovery should also be considered in combination. When a
trend of improvement in the standard criteria is absent, the
next evaluation after 7 days is not necessary; instead, the
drug should be discontinued and the administration of an
appropriate antimicrobial agent should be initiated.
Final evaluation
Evaluation of the clinical effect of a new antimicrobial
agent is usually completed along with the completion of the
treatment regime. However, a post-therapy follow-up ob-
servation may be necessary in particular patients depending
on the pathology and pathogenic organism concerned. For
example, a drug may be evaluated as effective initially in
some patients with severe pneumonia with underlying dis-
eases, or Mycoplasma pneumonia, or Chlamydia pneumo-
nia, but the infection may recar by the same pathogen at a
subsequent stage. Therefore, follow-up observations for a
deﬁned period of time are important to rule out such possi-
bilities. A 1-week period is considered to be adequate for
the follow-up evaluation of pneumonia, and this time the
evaluation is ﬁnal. During the evaluation of a new antimi-
crobial agent, the economic aspects of the drug should also
be assessed, in conjunction with its efﬁcacy and safety. If a
trial drug exhibits equal efﬁcacy to a similar existing drug(s)
with a fewer adverse reactions and, moreover, is economi-
cal, it is evaluated as superior to the existing drug(s). How-
ever, the standardized criteria and speciﬁc methods for
evaluation must be mentioned in the protocol in advance.
Clinical evaluation of new antimicrobial agents in
acute exacerbation of chronic pulmonary diseases
Acute exacerbation of chronic pulmonary diseases is almost
always attributable to an infection, and the pathogens are
often bacteria treatable with antimicrobial agents.44,45 This
section deals with deﬁning the guidelines for the selection
of patients, evaluation of the severity of the patient’s con-
dition, and evaluation of the efﬁcacy of the trial drug.
Disease concept and indications for clinical evaluation
of antimicrobial agents
Symptoms are acutely aggravated when an infection occurs
in patients with chronic pulmonary diseases with impaired
airway protectivity, such as chronic bronchitis, chronic
pulmonary emphysema, bronchiectasis, and diffuse pan-
bronchiolitis. Administration of antimicrobials should be
initiated at the earliest possible time. Sometimes, an acute
exacerbation is due more to an underlying disease or com-
plication rather than the infection itself. Acute exacerbation
due to bacterial causes is characterized by increased cough,
sputum production, and dyspnea, in addition to develop-
ment of sputum purulence. The amount of sputum and the
degree of purulence (purulent, muco-purulent, and mucoid)
are good indicators for clinical assessment. A suitable speci-
men of respiratory secretion is essential for identiﬁcation of
the etiologic pathogens. Isolation of the causative organism
is necessary for a proper evaluation of the efﬁcacy of the
study drug. The commonly encountered microorganisms in
acute exacerbation of chronic pulmonary diseases are
H. inﬂuenzae, S. pneumoniae, including other streptococci,
Moraxella (Branhamella) catarrhalis, and S. aureus, as
well as K. pneumoniae, Pseudomonas, and anaerobic
bacteria.44,45 Many of these microbes are established to
be involved in community-acquired infection, except for
methicillin-resistant Staphylococcus aureus (MRSA)
and Gram negative bacteria such as Pseudomonas.
In contrast, MRSA and Pseudomonas have been isolated
in patients with a long history of persistent infection
and comparatively severe underlying respiratory
diseases.46,47
Improvements in the symptoms and signs have mainly
been considered in the design of conventional evaluation
standards for the clinical effects of an antimicrobial agent,
whereas the effects of the drug on the etiologic agent have
not been given importance. Even though deterioration in
clinical condition can be assessed by increased body tem-
perature, peripheral white blood cell count, and CRP
values, the absence of fever and increased white blood cell
count do not rule out the possibility of acute exacerbation.
Analysis of conventional evaluation data has shown that
30%–40% of such patients did not have fever and an in-
crease in white blood cell count was observed in only 40%
of patients. Therefore, it is important to conduct the evalu-
ation of microbiological effects along with the clinical ef-
fects for a better outcome. The ESR, chest X-ray, and
arterial blood gas analysis may also be useful additional
tools.
Inclusion criteria for selection of patients
Patients enrolled in the study to evaluate the clinical effects
of a new antimicrobial agent should have a clinical diagnosis
of chronic pulmonary disease based on history, physical
examination, and radiographic examination. It is also neces-
sary to exclude the presence of chronic bronchitis and pneu-
monia. The standardized criteria for selection of patients
are as follows:
(a) Onset of cough and sputum or an increase in the volume
of sputum and/or worsening in the degree of purulence.
(b) Increase in CRP (0.7mg/dl or a value which exceeds
the facility’s maximum value).
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The following criteria are also to be satisﬁed while the
above two criteria are fulﬁlled.
(c) Microbiologic conﬁrmation of an etiologic pathogen by
Gram’s stain examination, and isolation on culture in a
suitable specimen. The specimen is considered to be
adequate when it contains 10 squamous epithelial
cells and 25 WBC per ﬁeld at 100  magniﬁcation.
(d) Fever (37°C).
(e) An increase in the peripheral white blood cell count
(8000/mm or a value which exceeds the facility’s
maximum value).
Standards for severity evaluation
The severity of the patient’s condition in acute exacerbation
of chronic pulmonary disease is affected by the severity of
underlying diseases and complications, as well as the sever-
ity of the infection itself. Respiratory function reserve is
already compromised in these patients, even in the absence
of infection, and therefore, microbial invasion worsens the
functional ability due to inﬂammation of the airway. The
underlying diseases and complications range from mild to
severe form, having very little to major effects, respectively,
on the onset and course of infection. Special attention
should be given to those patients with respiratory and car-
diac insufﬁciency, as they are prone to worsen easily.
The common indicators for assessment of severity of
infection include fever, peripheral white blood cell count,
and CRP values. But in some instances, cases such as aggra-
vation of persistent Pseudomonas infection in patients with
severe underlying lung diseases (such as severe diffuse
panbronchiolitis, bronchiectasis, old lung tuberculosis, and
tracheostomy) these indicators do not show signiﬁcant
changes, while dyspnea may become severe.
Severity of infection
Severity of infection in acute exacerbation of chronic pul-
monary diseases may be evaluated on the basis of fever,
peripheral white blood cell count, and CRP values, as
shown in Table 9. These three criteria are assessed on
the day of and 1 day prior to onset of treatment and
the higher values of the two are selected for evaluation.
However, it is presumed that these indicators for ev-
aluation are not caused by any underlying disease or
complication.
Severity of underlying diseases or complications
Underlying diseases and complications may be categorized
as mild, moderate, and severe.
Mild. Patients with a mild chronic pulmonary disease (such
as chronic bronchitis, chronic pulmonary emphysema, or
diffuse panbronchiolitis) and uncomplicated heart disease,
or with complications which do not affect the course of an
infection (such as mild hypertension, hyperlipidemia or
liver dysfunction).
Moderate. Patients with moderate chronic pulmonary dis-
eases and mild (latent) cardiac insufﬁciency, or with com-
plications which are expected not to have a major effect
on infection (such as controlled diabetes and chronic
nephritis).
Severe. Patients with chronic pulmonary disease accompa-
nied by respiratory insufﬁciency or cardiac insufﬁciency,
or with complications which affect the course of infec-
tion seriously (such as uncontrolled diabetes, including
ketoacidosis, connective tissue disease, tracheostomy, artiﬁ-
cial respiration, or advanced malignancy).
Severity of infection becomes intractable in patients with
severe underlying lung diseases and/or complications. If the
majority of the study population belong to this category,
appropriate evaluation of the trial drug may not be possible.
Severity of patient’s condition
Severity of the patient’s condition is evaluated on the basis
of a combined evaluation of severity of the infection and
severity of the underlying diseases and complications, as
shown in Table 10. As the severity of the patients condition
largely affects the course of infection, an appropriate analy-
sis is necessary for a better outcome of the trial. According
to the standardized criteria for the assessment of severity of
the patient’s condition, a patient with mild or moderate
infection may be evaluated as “severe” when the infection is
accompanied by severe underlying disease or complica-
tions. These subjects are usually not appropriate for clinical
evaluation of antimicrobial agents.
Table 9. Standardized criteria for evaluation of severity of disease in
patients with acute exacerbation of chronic pulmonary diseases
Parameters Severity of disease
Milda Moderateb Severec
Body temperature (°C) 37.5 39.0
Peripheral white blood 10000 15000
cell count (/mm3)
CRP (mg/dl) 5.0 10.0
a Satisﬁes all of the deﬁned criteria
b Cases which are neither mild nor severe
c Satisﬁes all of the deﬁned criteria
Table 10. Evaluation of severity of patients with acute exacerbation of
chronic pulmonary diseases
Severity of Severity of infection
underlying diseases
and complications Mild Moderate Severe
Mild Mild Moderate Severe
Moderate Moderate Moderate Severe
Severe Severe Severe Severe
Bold entries indicate patients who should be studied under special trial
settings
B. Jochimsen et al.: Stetteria hydrogenophila 121
Efﬁcacy evaluation standard
Determining the etiologic agent is necessary, as evaluation
of the characteristics of the antiinfective drug is premised
on the understanding that the etiologic agent is known. The
clinical ﬁndings, in combination with the change in the
course of an etiologic agent, should be investigated as
evaluation criteria in order to determine the extent to which
the in-vitro antimicrobial activity is reﬂected in the actual
treatment of an infection. Thus, evaluation of microbiologi-
cal effects, as well as clinical effects, is conducted 3 days
after commencement of the treatment and after the treat-
ment is complete (usually 7 days or a maximum of 14 days).
The ﬁrst evaluation after 3 days give an impression of the
trend of effectiveness of the study drug and speed of recov-
ery, and helps to decide whether to continue the drug.
Standards for evaluation of microbiological outcome
Identiﬁcation of the microbe by Gram staining of the smear
specimen is particularly useful before commencement of
the antimicrobial agent treatment. Isolation of the etiologic
agent from a specimen of respiratory secretion largely de-
pends on the quality of the specimen. A purulent sputum
specimen containing 25 WBC per ﬁeld and 10 squamous
epithelial cells at 100 magniﬁcation may provide a good
opportunity to determine the causative pathogen by Gram
staining and culture. In gross appearance, the sputum
should contain yellow or green portions which should be
used for tests. Care should be taken to avoid a false-
negative result often obtained by examining mucoid sputum
containing a lot of saliva. Mucoid sputum may be expecto-
rated even under stable conditions without infection in
patients with chronic bronchitis and chronic pulmonary em-
physema. An increase in the sputum volume is a sign of
exacerbation of infection, but if the sputum is mucoid, the
infection is viral in origin, and is not a target infection for
evaluation of antimicrobial agent therapy and, therefore,
should not be included in the evaluation study. When there
are inadequate and inefﬁcient supplies of specimen,
transtracheal aspiration or bronchoscopy may help in ob-
taining a quality sample of respiratory exudate.
Selection of the appropriate culture medium is also im-
portant for the correct identiﬁcation of the causative agent.
Usually, almost all aerobic bacteria can be isolated on a
blood agar or chocolate agar medium. Serological diagnos-
tic methods are not helpful in patients with acute exacerba-
tion of chronic lung diseases, in contrast to pneumonia.
Evaluation of the microbiological outcome may be con-
ducted using a similar standard procedure to that described
in the section. “Clinical evaluation of new antimicrobial
agents in acute respiratory tract infection”, subsection
“Standards for efﬁcacy evaluation; standards for evaluation
of microbiological outcome.”
Further, to evaluate the efﬁcacy of an antimicrobial
agent, in-vitro MIC (minimum inhibitory concentration)
and MBC (minimum bacterial concentration) may be ex-
amined. The MBC also provides information on the speed
of microbiologic recovery of the lesion. For example, a
specimen (such as sputum) collected from a patient before
and 3 days after commencement of a trial antimicrobial
agent and subjected to MBC investigation will give compa-
rable information on the effectiveness of the trial drug as
well as on the speed of elimination of the causative patho-
gen. Thus, quantitative information on the microbe, along
with the results of Gram staining and culture, will help in
the understanding of the nature and kinetics of infection. In
addition, useful information may also be obtained by mea-
suring the concentration of the trial drug in blood and in the
lesion.
Standards for evaluation of clinical outcome
The effectiveness of a new antimicrobial agent may be
shown by observation of the following improvements:
• An improvement in the cough.
• A reduction in the sputum volume to as low as almost half
of that before adiministration of the antimicrobial agent.
• A change in the sputum from purulent to mucopurulent or
mucoid, or from mucopurulent to mucoid.
• A return of body temperature to normal if there was fever
before treatment (fever is not observed in all patients, and a
previous clinical trial study of antimicrobial drugs in acute
exacerbation of chronic lung diseases reported that 40% of
the patients had a body temperature of 37°C or lower).
In addition to the above determinants, the peripheral white
blood cell count and CRP are also important indicators for
evaluation. The CRP is a very sensitive indicator for
tracking the effects of chemotherapy. A trial drug may be
evaluated as “effective” when the CRP value shows an
improvement or becomes negative. But there are excep-
tions to this observation. Even though peripheral white
blood cell count is an important indicator for evaluation of
the clinical effects of a new antimicrobial agent, previous
trials have shown that WBC count does not increase
(8000/mm3) in some patients (approximately 40%) with
chronic pulmonary diseases. Similarly, certain patients did
not show a clear-cut increase in CRP value (0.7mg/dl in
approximately 5% of the patients). In such patients, there-
fore, careful attention should be paid to clinical criteria,
such as cough and sputum, for evaluation. In addition,
peripheral WBC count and CRP values may ﬂuctuate due
to underlying conditions such as connective tissue diseases,
and the evaluation of the trial drug in such patients must be
conducted with great care. The standardized criteria for
evaluation of the clinical effects of a new antimicrobial drug
in patients with chronic pulmonary disease are summarized
in Table 11. As shown in Table 11, a drug would be consid-
ered “effective” when there is improvement in cough and
sputum condition and in addition, two out of the remaining
three criteria are satisﬁed and the other one is not wors-
ened. A failure to meet the above standardized criteria
would evaluate the trial drug as “ineffective”. Further, the
remark “evaluation not possible” is applied when the stan-
dardized criteria are beyond the scope of evaluation for any
reason. Efﬁcacy evaluation of the trial drug is conducted 3
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Closing remarks
The present report constitutes an attempt to improve and
modify the existing clinical evaluation methods for new
antimicrobial agents to treat respiratory infections. This
draft was constructed on the basis of analyzing large
amounts of material collected over years and incorporating
internal and external factors concerning the present evalua-
tion methods. The newly suggested standardized criteria for
clinical evaluation of the new antimicrobial drugs are ex-
pected to be practiced properly hereupon and subjected to
further improvement if necessary.
The volume of the fundamental material upon which the
evaluation standards have been set down is enormous and
should be discussed elsewhere, as it is beyond the scope of
this report. This information should be published in the
Journal of the Society by the respective concerned
committees.48
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Table 11. Evaluation of effectiveness of new antimicrobial agents in
patients with acute exacerbation of chronic pulmonary diseases
Parameters Criteria for effectiveness
Cough Improved in terms of severity
Sputum Improvement in degree of purulencea
Reduction in amountb
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